Results 231 to 240 of about 54,964,175 (374)

Mindfulness-Based Relapse Prevention for Substance Use Disorders: Effects on Cardiac Vagal Control and Craving Under Stress

, 2017
Haley A. Carroll, M. Kathleen B. Lustyk
openalex   +2 more sources

A potential role for the gut microbiome in substance use disorders

Psychopharmacology, 2019
Katherine R Meckel, D. Kiraly
semanticscholar   +1 more source

Personalizing the Treatment of Substance Use Disorders.

American Journal of Psychiatry, 2020
N. Volkow
semanticscholar   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Advancing social inclusion for people with co-occurring mental health and substance use disorders. [PDF]

World Psychiatry
Smelson D.
europepmc   +1 more source

Agreement between Youth Self-Report and Biospecimen-Confirmed Substance Use: A Systematic Review

, 2022
Johanna B. Folk, Matthew E. Hirschtritt, Quincy D. McCrary, Raj K. Kalapatapu   +3 more
openalex   +2 more sources

Screening for lung cancer: A systematic review of overdiagnosis and its implications

Molecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz, Laura de la Torre‐Perez, David R Baldwin, Carlijn van der Aalst, Mangesh Thorat, David Ritchie, Andre L Carvalho, Carolina Espina, Ivan Solà, Carlos Canelo‐Aybar, Moira Magdalena Pissinis, Pablo Alonso‐Coello, Ana Carolina Pereira Nunes Pinto   +12 more
wiley   +1 more source

A substance use relapse prevention programme for youth with substance use problems in Botswana. [PDF]

Health SA
Gaolaolwe W, Moagi MM, Kovane GP, Sehularo LA.   +3 more
europepmc   +1 more source

Gender differences in individuals with chronic pain and comorbid substance use

Iris Kovar-Gough, Jocelyn Zuckerman, Natoshia Cunningham, Rosa M. Limiñana-Gras, Mallet R. Reid, Carmen María Galvez Sánchez, Julio Ángel Camacho Ruiz   +6 more
openalex   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source